Highlights

Check out these recent Value Initiative highlights and accomplishments:

Value Initiative: Advocacy



President Vasken Dilizian, MD, Senator Ben Cardin,
Sukhjeet Ahuja MD, MS, Ira Goldman (Lantheus), and Rosemary Cioti (FORCE) meet to discuss H.R. 3772.
   SNMMI Members Talk Nuclear Medicine at Congressional Policy Briefing on Capitol Hill
On July 17, SNMMI co-hosted a briefing on Capitol Hill with clinicians, patients, and industry representatives to discuss the importance of nuclear medicine, diagnostic radiopharmacuticals, and specifically, H.R. 3772, also known as the Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019.

The bill calls for all diagnostic radiopharmaceuticals that reach a cost of more than $500 per day to be paid separately in the Hospital Outpatient Perspective Payment System.

Read the full release.
 
     

Value Initiative: Concept to Commercialization


   Concept to Commercialization
Dedicated session for small and emerging technology companies.
At the recent SNMMI Annual Meeting, experts from industry and venture capital organizations convened for a special session on facilitating a healthy molecular imaging and therapy ecosystem to grow innovative ideas into successful products that benefit patients. Core challenges specific to small and emerging technology companies, and ways to foster cross-sector partnerships were also addressed.
 
     


Value Initiative:
 Progress Report


   SNMMI's Value Initiative: A Progress Report 
In June 2019 at the SNMMI Annual Meeting in Anaheim, the Value Initiative Industry Alliance members met to review the latest progress, initiatives and future goals of the Value Initiative. View the Progress Report to learn more about the great work SNMMI is doing to further this vision.

View the Progress Report.
View the Presentation.
 
     


Domain Two: Research and Discovery

  Theranostics: Regulatory Considerations for Product Development
Sponsored by the Clinical Trials Network, the U.S. Food and Drug Administration, and the NCI.
In this highly attended session at the SNMMI 2019 Annual Meeting in Anaheim, California, speakers examined clinical, nonclinical and CMC information needed for theranostics product development, including a discussion on regulatory perspectives of products combining an imaging modality with therapeutic radiopharmaceuticals. The content of the session was specific to the needs of the community based on what FDA members in the Medical Imaging and other divisions are seeing in INDs, NDAs, aNDAs, and DMF applications filed with the agency and in other interactions with the community. 



Domain Two: Research and Discovery




   Theranostics Consensus Conference 2018
On November 8-9, SNMMI and the National Cancer Institute (NCI) hosted the Theranostics Consensus Conference 2018, sponsored by Progenics Pharmaceuticals. Attendees representing the major stakeholders in theranostics, including the FDA, NCI, academicians, clinical physicians, and pharmaceutical company executives gathered at the National Institutes of Health campus in Bethesda, Maryland, for two days of in-depth discussions.

The conference focused on key elements within this evolving field of nuclear medicine, including the current state of theranostic technology and challenges in trial design, as well as training and requirements needed for administration and dose planning. 

View Theranostics Conference presentation slides - November 8
View Theranostics Conference presentation slides - November 9
     
     
Value Initiative: Progress Report

   SNMMI's Value Initiative: A Progress Report
Through its Value Initiative, SNMMI is providing the strategic vision and roadmap to elevate nuclear medicine and molecular imaging, increasing its value to the medical community, regulators, patients and the public. Learn more about the great work SNMMI is doing to further this vision.
 
     

Domain Three: Workforce Pipeline and Life-Long Learning

   SNMMI Launches New Resident and Medical Student Website
This new site will help showcase the field as appealing to residents, and to promote awareness among medical students exploring future specialties. Its sleek design will provide clear, concise resources, news, and requested information to three main audience segments: medical students interested in the specialty, nuclear medicine and/or radiology residents, and program directors. 
     
Coming Soon! SNMMI will continue to enhance this new site, including working to provide Program Director resources through this site, and it is currently a forum to share feedback on what tools you’d like to see from the Society.


Domain Five: Outreach

     SNMMI’s Patient Advocacy Advisory Board Visits Capitol Hill
On March 14, members of SNMMI’s Patient Advocacy Advisory Board visited the Capitol Hill offices of 15 senators, 16 representatives, and two congressional committees to educate our legislators on the need for reformed coverage of diagnostic radiopharmaceuticals
     
  New Video Educates Patients on DaT SPECT
The SNMMI Brain Imaging Outreach Working Group’s “What to Expect” video for DaT SPECT offers a step-by-step guide to patients. The video received more than 3,000 views in its first month online. 
     
  Roadshows Spread the Word about Diagnosing and Treating NETs
The SNMMI Targeted Radioisotope Therapy Outreach Working Group has educated more than 300 physicians, techs, and patients on new developments in diagnosing and treating neuroendocrine tumors through its roadshow, which has traveled to Seattle, Salt Lake City, Phoenix, Dallas, and Washington, D.C. Next stops: Chicago, Portland, and Albuquerque.